Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy

Summary

Minocycline is the second generation of tetracycline. Because of its lipophilicity, it has high penetrance of blood-brain barrier. Animal model studies have shown that minocycline can reduce cerebral damage after ischemic stroke, and its mechanism involves multiple molecular pathways, such as antioxidant, anti-inflammatory, anti apoptotic pathways, and protection of blood-brain barrier. Clinical studies have also shown that minocycline can significantly improve 3-month National Institute of Health Stroke Scale (NIHSS) and modified Rankin Scale (mRS) of patients with ischemic stroke, indicating that minocycline is a potential neuroprotective drug. Minocycline is believed to protect the blood-brain barrier, thereby reducing the ischemia-reperfusion injury caused by mechanical thrombectomy. However, whether minocycline can become a synergistic treatment method of mechanical thrombectomy, there is no clinical research in this area at present. Therefore, investigators carry out the study on the effect of minocycline in patients with acute anterior circulation ischemic stroke after mechanical thrombectomy, and plan to enroll 180 patients. To explore the safety and effectiveness of minocycline in patients with acute ischemic stroke after thrombectomy.

Conditions

• Ischemic Stroke, Acute

Interventions

DRUG

Minocycline

Minocycline is a tetracycline antibiotic. Previous studies have confirmed that its application in stroke patients has good efficacy and safety, suggesting that it could become a synergistic treatment of mechanical thrombectomy.

Sponsors & Collaborators

• Xi'an No.3 Hospital

  collaborator OTHER_GOV

• Xi'an Gaoxin Hospital

  collaborator OTHER

• First People's Hospital of Xianyang

  collaborator OTHER

• Xi'an XD Group Hospital

  collaborator UNKNOWN

• Baoji High-tech Hospital

  collaborator UNKNOWN

• Weinan Central Hospital

  collaborator OTHER

• Xi'An Daxing Hospital

  collaborator UNKNOWN

• Yan'an University Xianyang Hospital

  collaborator UNKNOWN

• The First Hospital of Yulin

  collaborator UNKNOWN

• Northwest University First Hospital

  collaborator UNKNOWN

• Jingyang County Hospital

  collaborator UNKNOWN

• Yulin No.2 Hospital

  collaborator OTHER

• Yan'an people's Hospital

  collaborator UNKNOWN

• Yuncheng Central Hospital

  collaborator OTHER

• Second Affiliated Hospital of Xi'an Jiaotong University

  collaborator OTHER

• Xi'an No.9 Hospital

  collaborator UNKNOWN

• First Affiliated Hospital Xi'an Jiaotong University

  collaborator OTHER

• Pucheng County Hospital

  collaborator UNKNOWN

• Xijing Hospital

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-11-01

Primary Completion

2025-06-10

Completion

2025-09-10

Countries

• China

Study Locations